Rapid, serial, non-invasive assessment of drug efficacy in mice with autoluminescent Mycobacterium ulcerans infection.
Buruli ulcer (BU) caused by Mycobacterium ulcerans is the world's third most common mycobacterial infection. There is no vaccine against BU and surgery is needed for patients with large ulcers. Although recent experience indicates combination chemotherapy with streptomycin and rifampin improves...
Saved in:
Main Authors: | Tianyu Zhang (Author), Si-Yang Li (Author), Paul J Converse (Author), Jacques H Grosset (Author), Eric L Nuermberger (Author) |
---|---|
Format: | Book |
Published: |
Public Library of Science (PLoS),
2013-01-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
BCG-mediated protection against Mycobacterium ulcerans infection in the mouse.
by: Paul J Converse, et al.
Published: (2011) -
Activities of rifampin, Rifapentine and clarithromycin alone and in combination against mycobacterium ulcerans disease in mice.
by: Deepak Almeida, et al.
Published: (2011) -
Efficacy of Rifampin Plus Clofazimine in a Murine Model of Mycobacterium ulcerans Disease.
by: Paul J Converse, et al.
Published: (2015) -
Bactericidal activity does not predict sterilizing activity: the case of rifapentine in the murine model of Mycobacterium ulcerans disease.
by: Deepak V Almeida, et al.
Published: (2013) -
Accelerated detection of mycolactone production and response to antibiotic treatment in a mouse model of Mycobacterium ulcerans disease.
by: Paul J Converse, et al.
Published: (2014)